{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:10:03Z","timestamp":1748772603441,"version":"3.41.0"},"reference-count":162,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[1986,10,1]],"date-time":"1986-10-01T00:00:00Z","timestamp":528508800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medical Toxicology"],"published-print":{"date-parts":[[1986,10]]},"DOI":"10.1007\/bf03259848","type":"journal-article","created":{"date-parts":[[2016,2,7]],"date-time":"2016-02-07T20:31:25Z","timestamp":1454877085000},"page":"343-361","source":"Crossref","is-referenced-by-count":17,"title":["Adverse Reactions and Interactions with \u03b2-Adrenoceptor Blocking Drugs"],"prefix":"10.1007","volume":"1","author":[{"given":"R. V.","family":"Lewis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. G.","family":"McDevitt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,11,27]]},"reference":[{"key":"BF03259848_CR1","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1172\/JCI109781","volume":"65","author":"RD Aarons","year":"1980","unstructured":"Aarons RD, Nies AS, Gal J, et al. Elevation of \u03b2-adrenergic receptor density in human lymphocytes after propranolol administration. Journal of Clinical Investigation 65: 949, 1980","journal-title":"Journal of Clinical Investigation"},{"key":"BF03259848_CR2","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1111\/j.1365-2125.1982.tb01909.x","volume":"13","author":"WH Aellig","year":"1982","unstructured":"Aellig WH. Pindolol: a \u03b2-adrenoceptor blocking drug with partial agonist activity: clinical pharmacological considerations. British Journal of Clinical Pharmacology 13: 1875, 1982","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR3","first-page":"306","volume":"85","author":"SAH Al-Asady","year":"1985","unstructured":"Al-Asady SAH, Lennard MS, Shaw L, et al. Covalent binding of propranolol to rat and human liver microsomes: relation to inhibition of lignocaine metabolism. British Journal of Pharmacology 85: 306P, 1985","journal-title":"British Journal of Pharmacology"},{"key":"BF03259848_CR4","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1136\/bmj.1.5958.598","volume":"1","author":"HE Amos","year":"1975","unstructured":"Amos HE, Brigden WD, McKerron RA. Untoward effects associated with practolol: demonstration of antibody binding to epithelial tissue. British Medical Journal 1: 598\u2013600, 1975","journal-title":"British Medical Journal"},{"key":"BF03259848_CR5","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1136\/bmj.281.6250.1251-a","volume":"281","author":"CJ Anastassiades","year":"1981","unstructured":"Anastassiades CJ. Nifedipine and beta-blocker drugs. British Medical Journal 281: 1251\u20131252, 1981","journal-title":"British Medical Journal"},{"key":"BF03259848_CR6","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1001\/jama.1986.03370030077031","volume":"255","author":"J Avorn","year":"1986","unstructured":"Avorn J, Everitt D, Weiss S. Increased antidepressant use in patients prescribed \u03b2-blockers. Journal of the American Medical Association 255: 357\u2013360, 1986","journal-title":"Journal of the American Medical Association"},{"key":"BF03259848_CR7","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0035-8819(25)02672-8","volume":"16","author":"TR Bai","year":"1982","unstructured":"Bai TR, Webb D, Hamilton M. Treatment of hypertension with beta-adrenoceptor blocking drugs. Journal of the Royal College of Physicians (London) 16: 239\u2013241, 1982","journal-title":"Journal of the Royal College of Physicians (London)"},{"key":"BF03259848_CR8","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1136\/bmj.280.6219.976","volume":"280","author":"AH Barnett","year":"1980","unstructured":"Barnett AH, Leslie D, Watkins PJ. Can insulin treated diabetics be given beta-adrenergic blocking drugs? British Medical Journal 280: 976, 1980","journal-title":"British Medical Journal"},{"key":"BF03259848_CR9","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1111\/j.1365-2125.1985.tb02685.x","volume":"19","author":"NDS Bax","year":"1985","unstructured":"Bax NDS, Jones RW, Lennard MS, Tucker GT, Woods HF. Penbutolol and propranolol: a comparison of their effects on anti-pyrine clearance in man. British Journal of Clinical Pharmacology 19: 593\u2013596, 1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR10","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1111\/j.1365-2125.1984.tb02389.x","volume":"17","author":"NDS Bax","year":"1984","unstructured":"Bax NDS, Lennard MS, Tucker GT, et al. The effect of \u03b2-adrenoceptor antagonists on the pharmacokinetics and pharmacodynamics of warfarin after a single dose. British Journal of Clinical Pharmacology 17: 553\u2013557, 1984a","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR11","first-page":"597","volume":"19","author":"NDS Bax","year":"1984","unstructured":"Bax NDS, Tucker GT, Lennard MS, et al. The impairment of lignocaine clearance by propranolol: major contribution from enzyme inhibition. British Journal of Clinical Pharmacology 19: 597, 1984b","journal-title":"British Journal of Clinical Pharmacology"},{"issue":"2","key":"BF03259848_CR12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.2165\/00003495-198300252-00095","volume":"25","author":"DG Beevers","year":"1983","unstructured":"Beevers DG, Johnston JH, Larkin H, Davies P. Clinical evidence that \u03b2-adrenoceptor blockers prevent more cardiovascular complications than other antihypertensive drugs. Drugs 25 (Suppl. 2): 326\u2013330, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR13","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/bmj.288.6418.671","volume":"288","author":"C Bengtsson","year":"1984","unstructured":"Bengtsson C. Impairment of physical performance after treatment with beta-blockers and alpha blockers. British Medical Journal 288: 671\u2013672, 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR14","first-page":"467","volume":"21","author":"N Benowitz","year":"1973","unstructured":"Benowitz N, Rowland M, Forsyth R, Melman KL. Circulatory influences on lidocaine disposition. Clinical Research 21: 467, 1973","journal-title":"Clinical Research"},{"issue":"D","key":"BF03259848_CR15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1093\/eurheartj\/4.suppl_D.143","volume":"4","author":"EMM Besterman","year":"1983","unstructured":"Besterman EMM. How disturbing are the side effects of beta-blockers? European Heart Journal 4 (Suppl. D): 143\u2013145, 1983","journal-title":"European Heart Journal"},{"issue":"2","key":"BF03259848_CR16","doi-asserted-by":"crossref","first-page":"268","DOI":"10.2165\/00003495-198300252-00082","volume":"25","author":"TA Betts","year":"1983","unstructured":"Betts TA, Alford C. \u03b2-blocking drugs and sleep: a controlled trial. Drugs 25 (Suppl. 2): 268, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR17","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/BF00543709","volume":"28","author":"TA Betts","year":"1985","unstructured":"Betts TA, Knight R, Crowe A, Blake A, et al. Effect of \u03b2-blockers on psychomotor performance in normal volunteers. European Journal of Clinical Pharmacology 28 (Suppl.): 39\u201349, 1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR18","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.1001\/jama.1982.03320370021023","volume":"247","author":"BHAT Research Group.","year":"1982","unstructured":"BHAT Research Group. A randomised trial of propranolol in patients with acute myocardial infarction. Journal of the American Medical Association 247: 1707\u20131714, 1982","journal-title":"Journal of the American Medical Association"},{"key":"BF03259848_CR19","first-page":"956","volume":"30","author":"P Bielmann","year":"1981","unstructured":"Bielmann P, Leduc G, Jequier JC, et al. Changes in the lipoprotein composition after chronic administration of metoprolol and propranolol in hypertriglyceridemic-hypertensive subjects. Current Therapeutic Research 30: 956, 1981","journal-title":"Current Therapeutic Research"},{"key":"BF03259848_CR20","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1136\/bmj.284.6322.1095","volume":"284","author":"JN Blau","year":"1982","unstructured":"Blau JN. A plain man\u2019s guide to the treatment of migraine. British Medical Journal 284: 1095\u20131097, 1982","journal-title":"British Medical Journal"},{"key":"BF03259848_CR21","first-page":"235","volume":"7","author":"G Blohme","year":"1981","unstructured":"Blohme G, Lager I, Lonroth P, et al. Hypoglycaemic symptoms in insulin dependent diabetics: a prospective study of the influence of beta-blockers. Diabete et Metabolisme 7: 235, 1981","journal-title":"Diabete et Metabolisme"},{"key":"BF03259848_CR22","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1097\/00005344-198409000-00001","volume":"6","author":"JN Bloomquist","year":"1984","unstructured":"Bloomquist JN, Laddu A, Engler R. Adverse effects of acebutolol in chronic stable angina: drug-induced positive antinuclear antibody. Journal of Cardiovascular Pharmacology 6: 735\u2013738, 1984","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"BF03259848_CR23","first-page":"723","volume":"213","author":"PA Bond","year":"1967","unstructured":"Bond PA. Metabolism of propranolol (Inderal): a potent specific beta-adrenergic receptor blocking agent. Nature 213: 723, 1967","journal-title":"Nature"},{"key":"BF03259848_CR24","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00635706","volume":"78","author":"J Bonde","year":"1985","unstructured":"Bonde J, Bodtler S, Angelo T, Svendsen S, Kampmann JP. Atenolol inhibits the elimination of disopyramide. European Journal of Clinical Pharmacology 78: 41\u201343, 1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR25","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1111\/j.1365-2125.1977.tb00799.x","volume":"4","author":"Borg\u00e5","year":"1977","unstructured":"Borg\u00e5, Odar-Cederl\u00f6f I, Piafsky KM, Sj\u00f6gvist F. Plasma protein binding of propranolol in disease states. British Journal of Clinical Pharmacology 4: 627\u2013628, 1977","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR26","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0022-3565(25)29708-7","volume":"187","author":"RA Branch","year":"1973","unstructured":"Branch RA, Shand DG, Nies AS. Increase in hepatic blood flow and D-propranolol clearance by glucagon in the monkey. Journal of Pharmacology and Experimental Therapeutics 187: 581\u2013587, 1973","journal-title":"Journal of Pharmacology and Experimental Therapeutics"},{"key":"BF03259848_CR27","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1016\/S0140-6736(74)90218-9","volume":"2","author":"P Brown","year":"1974","unstructured":"Brown P, Baddeley H, Read AE, et al. Sclerosing peritonitis: an unusual reaction to a beta-adrenergic blocking drug (Practolol). Lancet 2: 1477, 1974","journal-title":"Lancet"},{"issue":"3","key":"BF03259848_CR28","doi-asserted-by":"crossref","first-page":"326","DOI":"10.7326\/0003-4819-95-3-326","volume":"95","author":"N Burgess-Record","year":"1981","unstructured":"Burgess-Record N. Acebutolol induced pleuropulmonary lupus syndrome. Annals of Internal Medicine 95(3): 326\u2013327, 1981","journal-title":"Annals of Internal Medicine"},{"key":"BF03259848_CR29","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1136\/bmj.286.6375.1439-b","volume":"286","author":"HA Cameron","year":"1983","unstructured":"Cameron HA, Ramsay LE. White beta-blocker (L)? British Medical Journal 286: 1439, 1983","journal-title":"British Medical Journal"},{"key":"BF03259848_CR30","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/S0140-6736(71)91372-9","volume":"2","author":"LCT Chang","year":"1971","unstructured":"Chang LCT. Use of practolol in asthmatics: a plea for caution. Lancet 2: 321, 1971","journal-title":"Lancet"},{"key":"BF03259848_CR31","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/clpt.1980.189","volume":"28","author":"KA Conrad","year":"1980","unstructured":"Conrad KA, Nyman DW. Effect of metoprolol and propranolol on theophylline elimination. Clinical Pharmacology and Therapeutics 28: 463\u2013467, 1980","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR32","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1007\/BF00543713","volume":"28","author":"JR Cove-Smith","year":"1985","unstructured":"Cove-Smith JR, Kirk AK. CNS-related side effects with metoprolol and atenolol. European Journal of Clinical Pharmacology 28 (Suppl.): 69, 1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR33","first-page":"309","volume":"7","author":"JM Cruickshank","year":"1981","unstructured":"Cruickshank JM. Beta-blockers, bradycardia and adverse effects. Acta Therapeutica 7: 309\u2013321, 1981","journal-title":"Acta Therapeutica"},{"key":"BF03259848_CR34","unstructured":"CSM (Committee on Safety of Medicines). Retroperitoneal fibrosis and beta-adrenoceptor antagonists. Current Patterns 6, 1981"},{"key":"BF03259848_CR35","first-page":"258","volume":"4","author":"J Cumberpatch","year":"1974","unstructured":"Cumberpatch J. Skin reactions to beta-blockers. British Medical Journal 4: 258, 1974","journal-title":"British Medical Journal"},{"key":"BF03259848_CR36","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/S0140-6736(81)92903-2","volume":"1","author":"TK Daneshmend","year":"1981","unstructured":"Daneshmend TK, Roberts CJC. Cimetidine and bioavailability of labetalol. Lancet 1: 565, 1981","journal-title":"Lancet"},{"key":"BF03259848_CR37","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1177\/003693307702200117","volume":"22","author":"N Davidson","year":"1976","unstructured":"Davidson NMcD, Corrall RJM, Shaw TRO, et al. Observations in man of hypoglycaemia during selective and non-selective beta-blockade. Scottish Medical Journal 22: 69, 1976","journal-title":"Scottish Medical Journal"},{"key":"BF03259848_CR38","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1136\/bmj.284.6323.1145","volume":"284","author":"JL Day","year":"1982","unstructured":"Day JL, Metcalfe J, Simpson CN. Adrenergic mechanisms in control of plasma lipid concentrations. British Medical Journal 284: 1145\u20131148, 1982","journal-title":"British Medical Journal"},{"key":"BF03259848_CR39","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/j.1365-2125.1981.tb01240.x","volume":"12","author":"CS Deacon","year":"1981","unstructured":"Deacon CS, Lennard MS, Bax NDS, Woods HF, Tucker GT. Inhibition of oxidative drug metabolism by beta-adrenoceptor antagonists is related to their solubility. British Journal of Clinical Pharmacology 12: 429\u2013430, 1981","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR40","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1136\/bmj.2.6030.272","volume":"2","author":"SP Deacon","year":"1976","unstructured":"Deacon SP, Barnett D. Comparison of atenolol and propranolol during insulin induced hypoglycaemia. British Medical Journal 2: 272, 1976","journal-title":"British Medical Journal"},{"key":"BF03259848_CR41","first-page":"887","volume":"21","author":"JH Dobbs","year":"1977","unstructured":"Dobbs JH, Skoutias VA, Acchiardo SR, Dobbs BR. Effects of aluminium hydroxide on the absorption of propranolol. Current Therapeutic Research: Clinical and Experimental 21: 887\u2013892, 1977","journal-title":"Current Therapeutic Research: Clinical and Experimental"},{"key":"BF03259848_CR42","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1136\/bmj.2.6154.1786-b","volume":"11","author":"CC Doherty","year":"1978","unstructured":"Doherty CC, McGeown MG, Donaldson RA. Retroperitoneal fibrosis after treatment with atenolol. British Medical Journal 11: 1786, 1978","journal-title":"British Medical Journal"},{"key":"BF03259848_CR43","doi-asserted-by":"crossref","unstructured":"Editorial. Long-term and short-term beta-blockade after myocardial infarction. Lancet 1: 1159, 1982","DOI":"10.1016\/S0140-6736(82)92230-9"},{"key":"BF03259848_CR44","doi-asserted-by":"crossref","unstructured":"Editorial. Is impotence an arterial disorder? Lancet 1: 181\u2013184, 1985","DOI":"10.1016\/S0140-6736(85)92023-9"},{"key":"BF03259848_CR45","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/BF00615401","volume":"20","author":"K Elliasson","year":"1981","unstructured":"Elliasson K, Lins LE, Rossner S. Serum lipoprotein changes during atenolol treatment of essential hypertension. European Journal of Clinical Pharmacology 20: 335\u2013338, 1981","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR46","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/clpt.1981.40","volume":"29","author":"H Elliot","year":"1981","unstructured":"Elliot H, McLean K, Sumner D, Meredith P, Reid JL. Immediate cardiovascular response to oral prazosin: effects of concurrent \u03b2-blockers. Clinical Pharmacology and Therapeutics 29: 303\u2013309, 1981","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR47","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/BF00627916","volume":"21","author":"ME Ellis","year":"1982","unstructured":"Ellis ME, Sahay JN, Chatterjee SS, Cruikshank JM, Ellis SH. Cardioselectivity of atenolol in asthmatic patients. European Journal of Clinical Pharmacology 21: 173, 1982","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR48","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1440-1681.1980.tb00078.x","volume":"7","author":"JDF England","year":"1980","unstructured":"England JDF, Simons LA, Gibson JC, Carlton M. The effect of metoprolol and atenolol on plasma high density lipoprotein levels in man. Clinical and Experimental Pharmacology and Physiology 7: 329\u2013333, 1980","journal-title":"Clinical and Experimental Pharmacology and Physiology"},{"key":"BF03259848_CR49","first-page":"114","volume":"186","author":"GH Evans","year":"1973","unstructured":"Evans GH, Nies AS, Shand DG. The disposition of propranolol. III: decreased half life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. Journal of Pharmacology and Experimental Therapeutics 186: 114\u2013119, 1973","journal-title":"III: decreased half life and volume of distribution as a result of plasma binding in man, monkey, dog and rat. Journal of Pharmacology and Experimental Therapeutics"},{"key":"BF03259848_CR50","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.1136\/bmj.289.6457.1490","volume":"289","author":"R F\u00e4ldt","year":"1984","unstructured":"F\u00e4ldt R, Liedholm H, Aursnes J. \u03b2-blockers and loss of hearing. British Medical Journal 289: 1490\u20131491. 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR51","first-page":"108","volume":"2","author":"JP Famey","year":"1979","unstructured":"Famey JP, Appelboom T. Leucocyte receptors to classical pharmacological mediators. European Journal of Rheumatology and Inflammation 2: 108\u2013114, 1979","journal-title":"European Journal of Rheumatology and Inflammation"},{"key":"BF03259848_CR52","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1056\/NEJM198103193041202","volume":"304","author":"J Feely","year":"1981","unstructured":"Feely J, Wilkinson GR, Wood AJJ. Reduction of liver blood flow and propranolol metabolism by cimetidine. New England Journal of Medicine 304: 692\u2013695, 1981","journal-title":"New England Journal of Medicine"},{"key":"BF03259848_CR53","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1111\/j.0954-6820.1983.tb03755.x","volume":"213","author":"E Feleke","year":"1983","unstructured":"Feleke E, Lyngstam O, Rastam L, Ryden L. Complaints of cold extremities among patients on antihypertensive treatment. Acta Medica Scandinavica 213: 381\u2013385, 1983","journal-title":"Acta Medica Scandinavica"},{"key":"BF03259848_CR54","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1097\/00007611-198002000-00030","volume":"73","author":"DS Fraley","year":"1976","unstructured":"Fraley DS, Bruns FJ, Segel DP, et al. Propranolol related bronchospasm in patients without history of asthma. Southern Medical Journal 73: 238, 1976","journal-title":"Southern Medical Journal"},{"issue":"2","key":"BF03259848_CR55","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2165\/00003495-198300252-00040","volume":"25","author":"S Freestone","year":"1983","unstructured":"Freestone S, Ramsay LE. Effect of \u03b2-blockade on the pressor response to coffee plus smoking in patients with mild hypertension. Drugs 25 (Suppl. 2): 141\u2013145, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR56","first-page":"1496","volume":"287","author":"JS Gill","year":"1983","unstructured":"Gill JS, Beevers DG. Hypertension and wellbeing. British Medical Journal 287: 1496, 1983","journal-title":"British Medical Journal"},{"key":"BF03259848_CR57","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1136\/bmj.1.6165.721-a","volume":"1","author":"R Gokal","year":"1979","unstructured":"Gokal R, Dornan RL, Ledingham JGG. Peripheral skin necrosis complicating beta-blockade. British Medical Journal 1: 721, 1979","journal-title":"British Medical Journal"},{"key":"BF03259848_CR58","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1161\/01.CIR.57.6.1161","volume":"57","author":"DJ Greenblatt","year":"1978","unstructured":"Greenblatt DJ, Franke K, Hoffman DH. Impairment of antipyrine clearance in humans by propranolol. Circulation 57: 1161\u20131164, 1978","journal-title":"Circulation"},{"key":"BF03259848_CR59","volume-title":"Cardiovascular Drugs","author":"DJ Greenblatt","year":"1977","unstructured":"Greenblatt DJ, Koch-Weser J. Clinical toxicity of propranolol and practolol: a report from the Boston Collaborative Drug Surveillance Program. In Avery (Ed.) Cardiovascular Drugs, Vol. 2, ADIS Press, Sydney, 1977"},{"key":"BF03259848_CR60","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1136\/bmj.282.6272.1321-b","volume":"2","author":"AD Harries","year":"1981","unstructured":"Harries AD. Beta-blockade in asthma. British Medical Journal 2: 1321, 1981","journal-title":"British Medical Journal"},{"issue":"2","key":"BF03259848_CR61","doi-asserted-by":"crossref","first-page":"136","DOI":"10.2165\/00003495-198300252-00039","volume":"25","author":"CM Hawksworth","year":"1983","unstructured":"Hawksworth CM, Dart AM, Chiang CS, Parry K, Petrie JC. Effect of oxprenolol on the pharmacokinetics and pharmacodynamics of hydralazine. Drugs 25 (Suppl. 2): 136\u2013140, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR62","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/bmj.284.6325.1304","volume":"184","author":"AM Heagerty","year":"1982","unstructured":"Heagerty AM, Castleden CM, Patel L. Failure of ranitidine to interact with propranolol. British Medical Journal 184: 1304, 1982","journal-title":"British Medical Journal"},{"key":"BF03259848_CR63","first-page":"696","volume":"15","author":"L Henri","year":"1981","unstructured":"Henri L, Groleau M. Retroperitoneal fibrosis after treatment with propranolol. Drug Intelligence and Clinical Pharmacy 15: 696, 1981","journal-title":"Drug Intelligence and Clinical Pharmacy"},{"key":"BF03259848_CR64","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1136\/bmj.289.6446.659-a","volume":"289","author":"SJ Hutchinson","year":"1984","unstructured":"Hutchinson SJ, Lorimer AR, Lakhdar A, McAlpine SG. \u03b2-Blockers and verapamil: a cautionary tale. British Medical Journal 289: 659\u2013660, 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR65","first-page":"26","volume":"11","author":"P Imhof","year":"1976","unstructured":"Imhof P. The significance of \u03b2-blockers with particular reference to antihypertensive treatment. Advances in Clinical Pharmacology 11: 26, 1976","journal-title":"Advances in Clinical Pharmacology"},{"key":"BF03259848_CR66","first-page":"274","volume":"20","author":"PR Jackson","year":"1985","unstructured":"Jackson PR, Lewis RV, Ramsay LE. \u03b2-Adrenoceptor antagonists and deafness. British Journal of Clinical Pharmacology 20: 274P, 1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR67","unstructured":"Johnsson G, Regardh CG. Haemodynamic interactions between adrenaline and beta-adrenoceptor antagonists in man and relationship between the effect and plasma levels of beta-adrenoceptor antagonists. Acta Physiologica Scandinavia (Suppl. 440): 28, 1976"},{"key":"BF03259848_CR68","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/0002-8703(80)90090-3","volume":"100","author":"L Kaijser","year":"1980","unstructured":"Kaijser L, Kaijser P, Karlsson J, R\u00f6ssner S. Beta-blockers and running. American Heart Journal 100: 943, 1980","journal-title":"American Heart Journal"},{"key":"BF03259848_CR69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1002\/art.1780230220","volume":"23","author":"R Kaplan","year":"1980","unstructured":"Kaplan R, Robinson CH, Scavulli JF, Vaughan JH. Propranolol and the treatment of rheumatoid arthritis. Arthritis and Rheumatism 23: 253\u2013255, 1980","journal-title":"Arthritis and Rheumatism"},{"issue":"2","key":"BF03259848_CR70","doi-asserted-by":"crossref","first-page":"241","DOI":"10.2165\/00003495-198300252-00069","volume":"25","author":"J Karlsson","year":"1983","unstructured":"Karlsson J. Muscle fibre composition, short term \u03b21 + \u03b22 and \u03b21-blockade and endurance exercise performance in healthy young men. Drugs 25 (Suppl. 2): 241\u2013246, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR71","unstructured":"Kauppinen K, Indanpaan-Heikkila J. Cutaneous reactions to beta-blocking agents. 15th International Congress of Dermatology, Mexico, 1977, p. 702, 1979"},{"key":"BF03259848_CR72","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1365-2125.1985.tb02634.x","volume":"19","author":"J Kelly","year":"1985","unstructured":"Kelly J, Salem S, Kinney C, Shanks R, McDevitt DG. Effects of ranitidine on the disposition of metoprolol. British Journal of Clinical Pharmacology 19: 219\u2013224, 1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR73","first-page":"33","volume":"15","author":"MJ Kendall","year":"1981","unstructured":"Kendall MJ. Are selective beta-adrenoceptor blocking drugs an advantage? Journal of the Royal College of Physicians 15: 33\u201340, 1981","journal-title":"Journal of the Royal College of Physicians"},{"key":"BF03259848_CR74","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/0163-7258(83)90060-8","volume":"21","author":"MJ Kendall","year":"1983","unstructured":"Kendall MJ, Beeley L. Beta-adrenoceptor blocking drugs: adverse reactions and drug interactions. Pharmacology and Therapeutics 21: 351\u2013369, 1983","journal-title":"Pharmacology and Therapeutics"},{"key":"BF03259848_CR75","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0140-6736(81)90921-1","volume":"2","author":"W Kirch","year":"1981","unstructured":"Kirch W, Kohler H, Spahn H, Mutschier E. Interaction of cimetidine with metoprolol, propranolol or atenolol. Lancet 2: 531\u2013532, 1981","journal-title":"Lancet"},{"key":"BF03259848_CR76","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1136\/pgmj.57.667.321","volume":"57","author":"A Kontopoulos","year":"1981","unstructured":"Kontopoulos A, Filindris A, Manoudis F, et al. Sotalol induced torsade de pointes. Postgraduate Medical Journal 57: 324, 1981","journal-title":"Postgraduate Medical Journal"},{"key":"BF03259848_CR77","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1136\/bmj.283.6285.191","volume":"283","author":"B Kristensen","year":"1981","unstructured":"Kristensen B\u00d8. Effect of long-term treatment with beta-blocking drugs on plasma lipids and lipoproteins. British Medical Journal 283: 191, 1981","journal-title":"British Medical Journal"},{"key":"BF03259848_CR78","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1136\/bmj.285.6348.1085-a","volume":"285","author":"M Laakso","year":"1982","unstructured":"Laakso M, Arvala I, Tervonen S, et al. Retroperitoneal fibrosis associated with sotalol. British Medical Journal 285: 1085\u20131086, 1982","journal-title":"British Medical Journal"},{"key":"BF03259848_CR79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1111\/j.1365-2125.1985.tb05062.x","volume":"20","author":"JWJ Lammers","year":"1985","unstructured":"Lammers JWJ, Folgering HT, van Herwaarden CLA. Ventilatory effects of long-term treatment with pindolol and metoprolol in hypertensive patients with chronic obstructive lung disease. British Journal of Clinical Pharmacology 20: 205\u2013210, 1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR80","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1056\/NEJM198212163072505","volume":"307","author":"MS Lennard","year":"1982","unstructured":"Lennard MS, Silas JM, Freestone S, et al. Oxidation phenotype: a major determinant of metoprolol metabolism and response. New England Journal of Medicine 307: 1558\u20131560, 1982","journal-title":"New England Journal of Medicine"},{"key":"BF03259848_CR81","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003088-198611010-00001","volume":"11","author":"MS Lennard","year":"1986","unstructured":"Lennard MS, Tucker GT, Woods HF. The polymorphic oxidation of \u03b2-adrenoceptor antagonists: clinical pharmacokinetic considerations. Clinical Pharmacokinetics 11: 1\u201317, 1986","journal-title":"Clinical Pharmacokinetics"},{"key":"BF03259848_CR82","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1172\/JCI108143","volume":"56","author":"JJ Lertora","year":"1975","unstructured":"Lertora JJ, Mark AL, Johannsen J, Wilson WR, Abboud FM. Selective beta-1 receptor blockade with oral practolol in man. Journal of Clinical Investigation 56: 719\u2013723, 1975","journal-title":"Journal of Clinical Investigation"},{"key":"BF03259848_CR83","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1111\/j.1365-2125.1984.tb05027.x","volume":"18","author":"M Lepantalo","year":"1984","unstructured":"Lepantalo M. Effects of metoprolol and alpha-methyldopa on calf blood flow. British Journal of Clinical Pharmacology 18: 90\u201393, 1984","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR84","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2125.1984.tb02471.x","volume":"18","author":"RV Lewis","year":"1984","unstructured":"Lewis RV, Jackson PR, Ramsay LE. Quantification of side effects of \u03b2-adrenoceptor blocking drugs using visual analogue scales. British Journal of Clinical Pharmacology 18: 325\u2013330, 1984","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR85","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1111\/j.1365-2125.1985.tb02639.x","volume":"19","author":"RV Lewis","year":"1985","unstructured":"Lewis RV, Jackson PR, Ramsay LE. Side effects of \u03b2-adrenoceptor blocking drugs assessed by visual analogue scales. British Journal of Clinical Pharmacology 19: 255\u2013257, 1985a","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR86","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/j.1365-2125.1985.tb02651.x","volume":"19","author":"RV Lewis","year":"1985","unstructured":"Lewis RV, Lennard MS, Jackson PR, et al. Timolol and atenolol: relationships between oxidation phenotype, pharmacokinetics and pharmacodynamics. British Journal of Clinical Pharmacology 19: 329\u2013333, 1985b","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR87","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1136\/bmj.292.6525.934-a","volume":"292","author":"RV Lewis","year":"1986","unstructured":"Lewis RV, Toner JM, Jackson PR, Ramsay LE. Effects of sulindac and indomethacin on the blood pressure of hypertensive patients. British Medical Journal 292: 934, 1986","journal-title":"British Medical Journal"},{"issue":"2","key":"BF03259848_CR88","doi-asserted-by":"crossref","first-page":"237","DOI":"10.2165\/00003495-198300252-00068","volume":"25","author":"J Lyngs\u00f8e","year":"1983","unstructured":"Lyngs\u00f8e J, Birk Lauridsen U, Christensen NJ. Effects of atenolol and propranolol on glucose metabolism and hormonal responses during insulin induced hypoglycaemia in normal man. Drugs 25 (Suppl. 2): 237\u2013240, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR89","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/j.1365-2125.1984.tb02343.x","volume":"17","author":"IA MacDonald","year":"1984","unstructured":"MacDonald IA, Bennet T, Brown AM, Wilcox RG, Skene AM. The effects of acute or chronic ingestion of propranolol or metoprolol on the metabolic and hormonal responses to prolonged, submaximal exercise in hypertensive men. British Journal of Clinical Pharmacology 17: 283\u2013293, 1984","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR90","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1002\/art.1780240324","volume":"24","author":"I Machtey","year":"1981","unstructured":"Machtey I. Polyarthritis following propranolol. Arthritis and Rheumatism 24: 568\u2013569, 1981","journal-title":"Arthritis and Rheumatism"},{"key":"BF03259848_CR91","first-page":"135","volume":"45","author":"AJ Marshall","year":"1977","unstructured":"Marshall AJ, Baddeley H, Barrett DW, et al. Practolol peritonitis. Quarterly Journal of Medicine 45: 135\u2013149, 1977","journal-title":"Quarterly Journal of Medicine"},{"key":"BF03259848_CR92","first-page":"74","volume":"53","author":"J McAinsh","year":"1977","unstructured":"McAinsh J. Clinical pharmacokinetics of atenolol. Postgraduate Medical Journal 53: 74\u201382, 1977","journal-title":"Postgraduate Medical Journal"},{"key":"BF03259848_CR93","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/bmj.288.6411.106","volume":"288","author":"D McAreavey","year":"1984","unstructured":"McAreavey D, Ramsay LE, Latham L, et al. \u2018Third drug\u2019 trial: comparative study of antihypertensive agents added to treatment when blood pressure remains uncontrolled by a beta-blocker plus thiazide diuretic. British Medical Journal 288: 106\u2013111, 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR94","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/bmj.281.6253.1459-a","volume":"281","author":"DR McCluskey","year":"1980","unstructured":"McCluskey DR, Donaldson RA, McGeown MG. Oxprenolol and retroperitoneal fibrosis. British Medical Journal 281: 1459\u20131460, 1980","journal-title":"British Medical Journal"},{"key":"BF03259848_CR95","unstructured":"McDevitt DG. In Petrie (Ed.) Clinically important adverse drug reactions, cardiovascular and respiratory disease therapy, Vol. 1, pp. 21\u201341, Elsevier\/North Holland Biomedical Press, 1980"},{"key":"BF03259848_CR96","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2165\/00003495-198325040-00001","volume":"25","author":"DG McDevitt","year":"1983","unstructured":"McDevitt DG. \u03b2-Adrenoceptor blocking drugs and partial agonist activity: is it clinically relevant? Drugs 25: 331, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR97","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/BF00543708","volume":"28","author":"DG McDevitt","year":"1985","unstructured":"McDevitt DG. \u03b2-Blockers and psychometric performance: studies in normal volunteers. European Journal of Clinical Pharmacology 28 (Suppl.): 35\u201338, 1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR98","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1002\/cpt1976202152","volume":"20","author":"DG McDevitt","year":"1976","unstructured":"McDevitt DG, Frisk-Holmberg M, Hollifield JW, Shand DG. Plasma binding and the affinity of propranolol for beta receptor in man. Clinical Pharmacology and Therapeutics 20: 152\u2013157, 1976","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR99","unstructured":"McDevitt DG, Harron DWG. Antianginal and \u03b2-adrenoceptor blocking drugs. In Meyler\u2019s side effects of drugs, 10th edition, Elsevier Science Publishers BV, 1986"},{"key":"BF03259848_CR100","unstructured":"Mclnnes GT, Findlay L, Murray GD, et al. Calcium antagonists and beta-blockers. In Calcium antagonists and the treatment of hypertension, Royal Society of Medicine, International Congress and Symposium Series, No. 62, 1985"},{"key":"BF03259848_CR101","unstructured":"Mclnnes GT, Thomson GD, Murray GD, Thomson GG, Brodie MJ. Intravenous verapamil during \u03b2-adrenoceptor blockade. British Journal of Clinical Pharmacology, 1986"},{"key":"BF03259848_CR102","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/clpt.1980.103","volume":"27","author":"AJ McLean","year":"1980","unstructured":"McLean AJ, Skews H, Bobik A, Dudley FJ. Interaction between oral propranolol and hydralazine. Clinical Pharmacology and Therapeutics 27: 726\u2013732, 1980","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"BF03259848_CR103","doi-asserted-by":"crossref","first-page":"131","DOI":"10.2165\/00003495-198300252-00038","volume":"25","author":"AJ McLean","year":"1983","unstructured":"McLean AJ, Wilhelm D, Heinzrow BG. Stable oral availability of atenolol coadministered with hydralazine. Drugs 25 (Suppl. 2): 131\u2013135, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR104","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1136\/bmj.2.6152.1598","volume":"2","author":"PD McSorley","year":"1978","unstructured":"McSorley PD, Warren DJ. Effects of propranolol and metoprolol on the peripheral circulation. British Medical Journal 2: 1598\u20131600, 1978","journal-title":"British Medical Journal"},{"key":"BF03259848_CR105","first-page":"539","volume":"2","author":"Medical Research Council Working Party on mild to moderate hypertension.","year":"1981","unstructured":"Medical Research Council Working Party (on mild to moderate hypertension). Adverse reactions to bendrofluazide and propranolol for the treatment of mild hypertension. Lancet 2: 539\u2013543, 1981","journal-title":"Lancet"},{"key":"BF03259848_CR106","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1136\/bmj.291.6488.97","volume":"291","author":"Medical Research Council Working Party.","year":"1985","unstructured":"Medical Research Council Working Party. M.R.C. trial of treatment of mild hypertension: principal results. British Medical Journal 291: 97\u2013104, 1985","journal-title":"British Medical Journal"},{"key":"BF03259848_CR107","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cpt1977221108","volume":"22","author":"A Melander","year":"1977","unstructured":"Melander A, Danielson K, Scherstein B, Wahlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clinical Pharmacology and Therapeutics 22: 108\u2013112, 1977","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR108","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1056\/NEJM197508282930902","volume":"293","author":"RR Miller","year":"1975","unstructured":"Miller RR, Olson HG, Amsterdam FA, et al. Propranolol withdrawal rebound phenomenon. New England Journal of Medicine 293: 416, 1975","journal-title":"New England Journal of Medicine"},{"key":"BF03259848_CR109","first-page":"21","volume":"16","author":"KP Minneman","year":"1979","unstructured":"Minneman KP, Hegstrand LR, Molinoff PB. The pharmacological specificity of beta 1 and beta 2 adrenergic receptors in rat heart and lung in vitro. Medical Pharmacology 16: 21\u201330, 1979","journal-title":"Medical Pharmacology"},{"key":"BF03259848_CR110","first-page":"365","volume":"76","author":"J Montoliu","year":"1981","unstructured":"Montoliu J, Botey A, Darnell A, et al. Prolonged hypotension after the first dose of atenolol. Medical Clinician (Barcelona) 76: 365, 1981","journal-title":"Medical Clinician (Barcelona)"},{"key":"BF03259848_CR111","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1161\/01.CIR.59.6.1158","volume":"59","author":"S Nattel","year":"1979","unstructured":"Nattel S, Rangno RE, Loon G. Mechanism of propranolol withdrawal phenomenon. Circulation 59: 1158, 1979","journal-title":"Circulation"},{"key":"BF03259848_CR112","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1111\/j.1365-2125.1981.tb01169.x","volume":"11","author":"G Neil-Dwyer","year":"1981","unstructured":"Neil-Dwyer G, Bartlett J, McAinsh J, Cruickshank JM. Beta-adrenoceptor blockers and the blood brain barrier. British Journal of Clinical Pharmacology 11: 549\u2013553, 1981","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR113","first-page":"242P","volume":"19","author":"SC Norris","year":"1985","unstructured":"Norris SC, Harry JD, Smith HJ, et al. Does ISA alter subjective awareness of \u03b2-adrenoceptor blockade? British Journal of Clinical Pharmacology 19: 242P, 1985","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR114","first-page":"823","volume":"2","author":"Norwegian Multicenter Study Group.","year":"1981","unstructured":"Norwegian Multicenter Study Group. Timolol induced reduction in mortality and reinfarction in patients surviving acute myocardial infarction. Lancet 2: 823, 1981","journal-title":"Lancet"},{"key":"BF03259848_CR115","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/clpt.1984.203","volume":"36","author":"H Ochs","year":"1984","unstructured":"Ochs H, Greenblatt D, Verburg-Ochs B. Propranolol interactions with diazepam lorazepam and alprazolam. Clinical Pharmacology and Therapeutics 36: 451, 1984","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR116","first-page":"88","volume":"2","author":"DA O\u2019Rourke","year":"1979","unstructured":"O\u2019Rourke DA, Donahue MF, Hayes JA. Beta-blockers and peripheral gangrene. Medical Journal of Australia 2: 88, 1979","journal-title":"Medical Journal of Australia"},{"key":"BF03259848_CR117","doi-asserted-by":"crossref","first-page":"3s","DOI":"10.1111\/j.1365-2125.1984.tb02422.x","volume":"17","author":"BK Park","year":"1984","unstructured":"Park BK. Prediction of metabolic drug interactions involving \u03b2-adrenoceptor blocking drugs. British Journal of Clinical Pharmacology 17: 3s\u201310s, 1984","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR118","doi-asserted-by":"crossref","first-page":"435S","DOI":"10.1111\/j.1365-2125.1982.tb01953.x","volume":"113","author":"C Pasotti","year":"1982","unstructured":"Pasotti C, Capra A, Fiorella G, et al. Effects of pindolol and metoprolol on plasma lipids and lipoproteins. British Journal of Clinical Pharmacology 113: 435S\u2013439S, 1982","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR119","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1002\/med.2610010405","volume":"1","author":"L Patel","year":"1981","unstructured":"Patel L, Turner P. Central actions of beta-adrenoceptor blocking drugs in man. Medical Research Reviews 1: 387\u2013410, 1981","journal-title":"Medical Research Reviews"},{"key":"BF03259848_CR120","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/j.1365-2125.1979.tb05812.x","volume":"8","author":"SB Pearson","year":"1979","unstructured":"Pearson SB, Banks DC, Patrick JM. The effect of \u03b2-adrenoceptor blockade on factors affecting exercise tolerance in normal man. British Journal of Clinical Pharmacology 8: 143\u2013148, 1979","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR121","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1136\/bmj.288.6433.1788","volume":"288","author":"NR Peden","year":"1984","unstructured":"Peden NR, Dow RJ, Isles TE, Martin BT. \u03b2-Adrenoceptor blockade and responses of serum lipids to a meal and to exercise. British Medical Journal 288: 1788\u20131790, 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR122","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S0140-6736(80)92135-2","volume":"2","author":"M Peet","year":"1980","unstructured":"Peet M, Middlemiss DN, Yates RA. Pharmacokinetic interaction between propranolol and chlorpromazine in schizophrenic patients. Lancet 2: 978, 1980","journal-title":"Lancet"},{"key":"BF03259848_CR123","first-page":"155","volume":"6","author":"M Peet","year":"1981","unstructured":"Peet M, Yates RA. Beta-blockers in the treatment of neurological and psychiatric disorders. Journal of Clinical Hospital Pharmacy 6: 155\u2013171, 1981","journal-title":"Journal of Clinical Hospital Pharmacy"},{"key":"BF03259848_CR124","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1176\/ajp.139.1.92","volume":"139","author":"WM Petrie","year":"1982","unstructured":"Petrie WM, Mafucci RJ, Woosley RC. Propranolol and depression. American Journal of Psychiatry 139: 92, 1982","journal-title":"American Journal of Psychiatry"},{"key":"BF03259848_CR125","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1001\/jama.1983.03330270063039","volume":"249","author":"TG Pickering","year":"1983","unstructured":"Pickering TG. Treatment of mild hypertension and the reduction of cardiovascular mortality: the \u2018of or by\u2019 dilemma. Journal of the American Medical Association 249: 399\u2013400, 1983","journal-title":"Journal of the American Medical Association"},{"key":"BF03259848_CR126","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/0002-9149(66)90061-0","volume":"18","author":"BNC Prichard","year":"1966","unstructured":"Prichard BNC, Ross EJ. Use of propranolol in conjunction with alpha receptor blocking drugs in phaeochromocytoma. American Journal of Cardiology 18: 394\u2013398, 1966","journal-title":"American Journal of Cardiology"},{"key":"BF03259848_CR127","first-page":"1917","volume":"1","author":"JP Pryor","year":"1982","unstructured":"Pryor JP, Castle WM. Peyronie\u2019s disease associated with chronic degenerative arterial disease and not with beta-adrenoceptor blocking agents. Lancet 1: 1917, 1982","journal-title":"Lancet"},{"key":"BF03259848_CR128","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1136\/bmj.287.6393.639","volume":"287","author":"JP Pryor","year":"1983","unstructured":"Pryor JP, Castle WM, Dukes DL, et al. Do beta-adrenoceptor blocking drugs cause retroperitoneal fibrosis? British Medical Journal 287: 639\u2013640, 1983","journal-title":"British Medical Journal"},{"key":"BF03259848_CR129","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1136\/bmj.282.6263.548","volume":"1","author":"JM Raine","year":"1981","unstructured":"Raine JM, Palazzo MG, Kerr JH, et al. Near fatal bronchospasm after oral nadolol in a young asthmatic response to ventilation with halothane. British Medical Journal 1: 548, 1981","journal-title":"British Medical Journal"},{"key":"BF03259848_CR130","doi-asserted-by":"crossref","first-page":"345S","DOI":"10.1111\/j.1365-2125.1982.tb01939.x","volume":"13","author":"RE Rangno","year":"1982","unstructured":"Rangno RE, Langlois S. Comparison of withdrawal phenomena after propranolol, metoprolol and pindolol. British Journal of Clinical Pharmacology 13: 345S, 1982","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR131","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/clpt.1982.2","volume":"31","author":"RE Rangno","year":"1982","unstructured":"Rangno RE, Langlois S, Lutterodt A. Metoprolol withdrawal phenomena: mechanism and prevention. Clinical Pharmacology and Therapeutics 31: 8, 1982","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR132","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1136\/bmj.1.6168.955-b","volume":"2","author":"PJ Rees","year":"1979","unstructured":"Rees PJ. Peripheral skin necrosis complicating beta-blockade. British Medical Journal 2: 955, 1979","journal-title":"British Medical Journal"},{"key":"BF03259848_CR133","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1002\/cpt1975175612","volume":"17","author":"N Reichert","year":"1975","unstructured":"Reichert N, Shibolet A, Adar R, et al Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics 17: 612, 1975","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"BF03259848_CR134","first-page":"S201","volume":"4","author":"S Rossner","year":"1982","unstructured":"Rossner S. Serum lipoproteins and ischaemic vascular disease: on the interpretation of serum lipid versus serum lipoprotein concentrations. Journal of Cardiovascular Pharmacology 4 (Suppl. 2): S201\u2013S205, 1982","journal-title":"Journal of Cardiovascular Pharmacology"},{"issue":"2","key":"BF03259848_CR135","doi-asserted-by":"crossref","first-page":"322","DOI":"10.2165\/00003495-198300252-00094","volume":"25","author":"S Rossner","year":"1983","unstructured":"Rossner S, Weiner L. A comparison of the effects of atenolol and metoprolol on serum lipoproteins. Drugs 25 (Suppl. 2): 322\u2013325, 1983","journal-title":"Drugs"},{"issue":"2","key":"BF03259848_CR136","doi-asserted-by":"crossref","first-page":"256","DOI":"10.2165\/00003495-198300252-00077","volume":"25","author":"JR Ryan","year":"1983","unstructured":"Ryan JR, Lacorte W, Jain A, McMahon FG. Response of diabetics treated with atenolol or propranolol to insulin induced hypoglycaemia. Drugs 25 (Suppl. 2): 256\u2013257, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR137","first-page":"134","volume":"23","author":"B Santoso","year":"1985","unstructured":"Santoso B. Impairment of isoniazid clearance by propranolol. International Journal of Clinical Pharmacology, Therapy and Toxicology 23: 134\u2013136, 1985","journal-title":"International Journal of Clinical Pharmacology, Therapy and Toxicology"},{"key":"BF03259848_CR138","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1136\/bmj.287.6401.1256","volume":"287","author":"J Savola","year":"1983","unstructured":"Savola J. Arthropathy induced by beta-blockade. British Medical Journal 287: 1256\u20131257, 1983","journal-title":"British Medical Journal"},{"key":"BF03259848_CR139","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/clpt.1983.34","volume":"33","author":"M Schafer-Korting","year":"1984","unstructured":"Schafer-Korting M, Kirch W, Axhelm T, Kohler H, Mutschier E. Atenolol interaction with aspirin, allopurinol and ampicillin. Clinical Pharmacology and Therapeutics 33: 283\u2013288, 1984","journal-title":"Clinical Pharmacology and Therapeutics"},{"issue":"2","key":"BF03259848_CR140","doi-asserted-by":"crossref","first-page":"92","DOI":"10.2165\/00003495-198300252-00031","volume":"25","author":"DG Shand","year":"1983","unstructured":"Shand DG. Comparative pharmacology of the \u03b2-adrenoceptor blocking drugs. Drugs 25 (Suppl. 2): 92\u201399, 1983","journal-title":"Drugs"},{"key":"BF03259848_CR141","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/cpt1970111112","volume":"11","author":"DG Shand","year":"1970","unstructured":"Shand DG, Nuckolls EM, Oates JA. Plasma propranolol levels in adults. Clinical Pharmacology and Therapeutics 11: 112\u2013120, 1970","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR142","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1111\/j.1365-2125.1983.tb01539.x","volume":"15","author":"H Spahn","year":"1983","unstructured":"Spahn H, Kirch W, Mutschier E. The interaction of cimetidine with metoprolol, atenolol, propranolol and pindolol and penbutolol. British Journal of Clinical Pharmacology 15: 500\u2013501, 1983a","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR143","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1136\/bmj.286.6377.1546","volume":"286","author":"H Spahn","year":"1983","unstructured":"Spahn H, Mutschler E, Kirch W, Ohnhaus EE, Janisch HD. Influence of ranitidine on plasma metoprolol and atenolol concentrations. British Medical Journal 286: 1546\u20131547, 1983b","journal-title":"British Medical Journal"},{"key":"BF03259848_CR144","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1136\/bmj.282.6259.225-a","volume":"282","author":"JS Stafforth","year":"1981","unstructured":"Stafforth JS, Emery P. Adverse interaction between nifedipine and beta-blockade. British Medical Journal 282: 225, 1981","journal-title":"British Medical Journal"},{"key":"BF03259848_CR145","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1038\/clpt.1981.100","volume":"29","author":"TL Svendson","year":"1981","unstructured":"Svendson TL, Hartling OJ, Trap-Jenson J, et al. Adrenergic beta receptor blockade: haemodynamic importance of intrinsic sympathomimetic activity at rest. Clinical Pharmacology and Therapeutics 29: 711\u2013718, 1981","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR146","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/S0140-6736(81)91105-3","volume":"2","author":"SH Taylor","year":"1981","unstructured":"Taylor SH, Silke B. Haemodynamic effects of beta blockade in ischaemic heart failure. Lancet 2: 835, 1981","journal-title":"Lancet"},{"key":"BF03259848_CR147","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1136\/bmj.284.6309.83-a","volume":"284","author":"J Thompson","year":"1982","unstructured":"Thompson J, Julian DG. Retroperitoneal fibrosis associated with metoprolol. British Medical Journal 284: 83\u201384, 1982","journal-title":"British Medical Journal"},{"key":"BF03259848_CR148","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1111\/j.1365-2125.1982.tb04967.x","volume":"14","author":"GT Tucker","year":"1982","unstructured":"Tucker GT, Bax NDS, Lennard MS, Creve K, Woods UF. Lack of effect of atenolol on antipyrene clearance. British Journal of Clinical Pharmacology 14: 743\u2013745, 1982","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR149","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1136\/bmj.289.6440.288-a","volume":"289","author":"CP Venter","year":"1984","unstructured":"Venter CP, Joubert PH, Buys AC. Severe peripheral ischaemia during concomitant use of beta blockers and ergot alkaloids. British Medical Journal 289: 788\u2013789, 1984","journal-title":"British Medical Journal"},{"key":"BF03259848_CR150","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1002\/cpt197925119","volume":"25","author":"RE Vestal","year":"1979","unstructured":"Vestal RE, Kornhauser DM, Hollifield JW, Shand DG. Inhibition of propranolol metabolism by chlorpromazine. Clinical Pharmacology and Therapeutics 25: 19\u201324, 1979","journal-title":"Clinical Pharmacology and Therapeutics"},{"key":"BF03259848_CR151","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1136\/bmj.2.6033.453","volume":"2","author":"JR Vilsvik","year":"1976","unstructured":"Vilsvik JR, Schaaning J. Effect of atenolol on ventilatory and cardiac function in asthma. British Medical Journal 2: 453\u2013455, 1976","journal-title":"British Medical Journal"},{"key":"BF03259848_CR152","doi-asserted-by":"crossref","first-page":"359S","DOI":"10.1111\/j.1365-2125.1982.tb01941.x","volume":"13","author":"RJ Waiden","year":"1982","unstructured":"Waiden RJ, Bhattacharjee P, Tomlinson B, et al. The effect of intrinsic sympathomimetic activity on \u03b2-receptor responsiveness after \u03b2-adrenoceptor blockade withdrawal. British Journal of Clinical Pharmacology 13: 359S, 1982","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR153","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1136\/bmj.291.6510.1684","volume":"291","author":"PC Waller","year":"1985","unstructured":"Waller PC, Ramsay LE. Do \u03b2-blockers cause arthropathy: a case control study. British Medical Journal 291: 1684, 1985","journal-title":"British Medical Journal"},{"key":"BF03259848_CR154","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1136\/bmj.281.6242.702","volume":"281","author":"J Watkins","year":"1980","unstructured":"Watkins J, Carl Abbot E, Hensby C, et al. Attenuation of hypotensive effect of propranolol and thiazide diuretics by indomethacin. British Medical Journal 281: 702\u2013705, 1980","journal-title":"British Medical Journal"},{"key":"BF03259848_CR155","doi-asserted-by":"crossref","first-page":"32","DOI":"10.2165\/00003495-198530010-00004","volume":"30","author":"J Webster","year":"1985","unstructured":"Webster J. Interactions of NSAIDs with diuretics and \u03b2-blockers: mechanisms and clinical implications. Drugs 30: 32\u201341, 1985","journal-title":"Drugs"},{"key":"BF03259848_CR156","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF00543714","volume":"28","author":"A Westerlund","year":"1985","unstructured":"Westerlund A. Central nervous system side effects with hydrophilic and lipophilic \u03b2-blockers. European Journal of Clinical Pharmacology 28 (Suppl.): 73\u201376, 1985","journal-title":"European Journal of Clinical Pharmacology"},{"key":"BF03259848_CR157","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/j.1365-2125.1984.tb02342.x","volume":"17","author":"RG Wilcox","year":"1984","unstructured":"Wilcox RG, Bennet T, MacDonald IA, Herbert M, Skene AM. The effects of acute or chronic ingestion of propranolol or metoprolol on the physiological responses to prolonged, submaximal increase in hypertensive man. British Journal of Clinical Pharmacology 17: 273\u2013281, 1984","journal-title":"British Journal of Clinical Pharmacology"},{"key":"BF03259848_CR158","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/S0140-6736(86)91271-7","volume":"1","author":"DG Wong","year":"1986","unstructured":"Wong DG, Spence JD, Lamki L, Freeman D, MacDonald J. Effect of non steroidal antiinflammatory drugs on control of hypertension by \u03b2-blockers and diuretics. Lancet 1: 997\u20131001, 1986","journal-title":"Lancet"},{"key":"BF03259848_CR159","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1136\/bmj.1.6157.159","volume":"1","author":"AD Wright","year":"1979","unstructured":"Wright AD, Barber SG, Kendall MJ, et al. Beta-adrenoceptor blocking drugs and blood sugar control in diabetes mellitus. British Medical Journal 1: 159, 1979","journal-title":"British Medical Journal"},{"key":"BF03259848_CR160","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1136\/bmj.1.5958.595","volume":"1","author":"P Wright","year":"1975","unstructured":"Wright P. Untoward effects associated with practolol administration: oculomucocutaneous syndrome. British Medical Journal 1: 595\u2013598, 1975","journal-title":"British Medical Journal"},{"issue":"4","key":"BF03259848_CR161","first-page":"87","volume":"52","author":"FJ Zacharias","year":"1976","unstructured":"Zacharias FJ. Patient acceptability of propranolol and the occurrence of side effects. Postgraduate Medical Journal 52 (Suppl. 4): 87\u201389, 1976","journal-title":"Postgraduate Medical Journal"},{"key":"BF03259848_CR162","first-page":"102","volume":"53","author":"FJ Zacharias","year":"1977","unstructured":"Zacharias FJ, Cowan KJ, Cuthbertson PJR, et al. Atenolol in hypertension: a study of long-term therapy. Postgraduate Medical Journal 53 (Suppl. 3): 102, 1977","journal-title":"Postgraduate Medical Journal"}],"container-title":["Medical Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259848.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/BF03259848\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03259848","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T09:52:34Z","timestamp":1748771554000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/BF03259848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1986,10]]},"references-count":162,"journal-issue":{"issue":"5","published-print":{"date-parts":[[1986,10]]}},"alternative-id":["BF03259848"],"URL":"https:\/\/doi.org\/10.1007\/bf03259848","relation":{},"ISSN":["0112-5966"],"issn-type":[{"type":"print","value":"0112-5966"}],"subject":[],"published":{"date-parts":[[1986,10]]}}}